In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solu...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...